Company / Cash & Equivalents
Design Therapeutics, Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$16.9M
FY2025
5-year range
$16.9M / $298.6M
FY2021-FY2025
Trend
-25.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $299M to $17M over the past 4 years.
Based on SEC 10-K filings.
$17M in FY2025.
Declined from $299M to $17M over the past 4 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 25.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.9M | -25.3% |
| FY2024 | $22.6M | -92.4% |
| FY2021 | $298.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026